AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9494772
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg norethisterone acetate
Trial: 9494772
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg norethisterone acetate
Trial: 7692687
Drug: 3-week therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week therapy series of ultrasound (6 times a week)
Trial: 7692687
Drug: 6-week therapy
RxNorm normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-week therapy series of ultrasound (3 times a week)
Trial: 7692687
Drug: 9-week therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-week therapy series of ultrasound (2 times a week)
Trial: 26823602
Drug: First-line bevacizumab-based
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First-line bevacizumab-based therapy
Trial: 22496207
Drug: Sulfasalazine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (4 days treatment, n = 5)
Trial: 22496207
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no treatment, n = 5)
Trial: 22496207
Drug: Sulfasalazine (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (long-term treatment)
Trial: 2989349
Drug: Placebo (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (long-term treatment)
Trial: 19085342
Drug: Candesartan-HCT 32/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan-HCT 32/12.5 mg
Trial: 19085342
Drug: Candesartan-HCT 32/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan-HCT 32/25 mg
Trial: 10357049
Drug: Teicoplanin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (400 mg)
Trial: 8733702
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol for mucositis prophylaxis
Trial: 1656517
Drug: 2.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g/day omega-3-PUFA
Trial: 1656517
Drug: 4.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 g/day omega-3-PUFA
Trial: 31490536
Drug: Clopidogrel bisulphate
RxNorm normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel bisulphate plus aspirin (600 mg on day 1, then 75 mg per day through day 90; plus 50 to 325 mg of aspirin per day)
Trial: 31490536
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus aspirin (same range of dosages as clopidogrel)
Trial: 31490536
Drug: Clopidogrel bisulphate
RxNorm normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel bisulphate plus aspirin
Trial: 25311333
Drug: Single-arm trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-arm trial intervention including a one-time, half-day educational session with targeted sexual health education, body awareness and relaxation training, and mindfulness-based cognitive therapy strategies, followed by two sessions of tailored telephone counseling.
Trial: 12462350
Drug: Porcine secretin
RxNorm normalized name: Porcine secretin
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine secretin infusions
Trial: 12462350
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human secretin infusions
Trial: 9199740
Drug: Timolol (as
RxNorm normalized name: timolol (as maleate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (as add-on therapy)
Trial: 1756844
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (1.6 mg daily)
Trial: 6961762
Drug: Labetalol 200
RxNorm normalized name: HCTZ 25/LABETALOL 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 200 mg i.v. over 5 min
Trial: 6961762
Drug: Labetalol 200
RxNorm normalized name: HCTZ 25/LABETALOL 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 200 mg orally
Trial: 6961762
Drug: Labetalol 400
RxNorm normalized name: labetalol 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 400 mg orally
Trial: 29024278
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitor dapagliflozin
Trial: 29145894
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of myo‐inositol twice daily for 12 months
Trial: 29145894
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo twice daily for 12 months
Trial: 23084759
Drug: Control (C)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (C) treatment with 150g/d of diet
Trial: 17238884
Drug: Bilateral infraorbital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral infraorbital nerve block (Group B) with 1 ml 0.25% bupivacaine and 2 ml i.v. saline as control
Trial: 15960852
Drug: Self-testing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-testing of blood glucose group; interpreted with nurse-practitioner to inform adjustment of medication
Trial: 15960852
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with three monthly HbA1c measurements; interpreted with nurse-practitioner
Trial: 26436470
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitors (general)
Trial: 12196361
Drug: 8-week VNCOP-B
RxNorm normalized name: sennosides, USP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week VNCOP-B plus G-CSF regimen
Trial: 12196361
Drug: 12-week VNCOP-B
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week VNCOP-B plus G-CSF regimen
Trial: 9465841
Drug: Sirolimus and
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus and cyclosporine administered concomitantly (schedule I)
Trial: 9465841
Drug: Sirolimus administered
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus administered 4 hours after cyclosporine (schedule II)
Trial: 2649124
Drug: Metoprolol 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 0.07 mg kg‐1 i.v. (9 patients)
Trial: 2649124
Drug: Captopril 1
RxNorm normalized name: captopril 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 1 mg kg‐1 by mouth (11 patients)
Trial: 26927900
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron isomaltoside
Trial: 26927900
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron isomaltoside infusion
Trial: 26927900
Drug: Iron isomaltoside
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron isomaltoside infusion
Trial: 26927900
Drug: Iron isomaltoside
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron isomaltoside bolus injection
Trial: 20696980
Drug: Adherent group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherent group (those who stayed on treatment)
Trial: 20696980
Drug: Nonadherent group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadherent group (those who discontinued treatment)
Trial: 15813831
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg twice daily
Trial: 7544175
Drug: 35 g
RxNorm normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 g resistant starch (100 g amylomaize starch)
Trial: 2671116
Drug: Silymarin (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (140 mg three times daily)
Trial: 26429655
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate 2 mg/kg/d for six months
Trial: 23954071
Drug: Combined pharmacotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pharmacotherapy (bupropion SR + nicotine lozenge, nicotine patch + nicotine lozenge)
Trial: 23954071
Drug: Monotherapy (bupropion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (bupropion SR, nicotine patch, nicotine lozenge)
Trial: 15151958
Drug: Hemoglobin responders
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin responders (increase > or =2 g/dl)
Trial: 8288662
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg enoxaparin every 12 hours (194 patients)
Trial: 8288662
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg enoxaparin once daily (203 patients)
Trial: 8288662
Drug: 5000 units
RxNorm normalized name: A-25, 25000 units oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 units unfractionated heparin every 8 hours (207 patients)
Trial: 27434056
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg L-homoarginine once daily for 4 weeks
Trial: 20826244
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose, followed by 75 mg daily) in addition to aspirin
Trial: 18028997
Drug: Intranasal CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal CO2 treatment
Trial: 9556010
Drug: Placebo (air)
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (air) treatment
Trial: 3816290
Drug: Merieux rubella
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merieux rubella vaccine
Trial: 3816290
Drug: Wellcome RA27/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wellcome RA27/3 rubella vaccine
Trial: 3816290
Drug: Low pre-vaccine
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low pre-vaccine titre subjects
Trial: 3816290
Drug: High pre-vaccine
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High pre-vaccine titre subjects
Trial: 29808324
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO), treated once daily at a pressure of 2.0 atm absolute with 100% oxygen.
Trial: 29808324
Drug: No hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hyperbaric oxygen therapy (no-HBO), standard arm.
Trial: 22119930
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 μg/kg subcutaneously, 12 doses)
Trial: 20124207
Drug: Pregabalin (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (average daily dosage 385.7 mg/d)
Trial: 16202888
Drug: 12 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/kg/d zoniporide
Trial: 12134176
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AEDs) treatment for 6 months in group A
Trial: 12134176
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AEDs) treatment for 1 year in group B
Trial: 7539873
Drug: Chemotherapy (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin 20 mg/m2 day 1-5, bleomycin 10 mg/m2 continuous infusion from day 3-7, methotrexate 40 mg/m2 on day 15 and day 22, repeated on day 29 for two cycles)
Trial: 7539873
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (surgery + radiation)
Trial: 20679501
Drug: Single 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 150 mg dose of caspofungin
Trial: 20679501
Drug: Single 210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 210 mg dose of caspofungin
Trial: 20679501
Drug: Multiple 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple 100 mg doses of caspofungin for 21 days
Trial: 19729951
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) for 6 months
Trial: 17241413
Drug: BoNTA(2) (Dysport,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNTA(2) (Dysport, Ipsen Ltd.) at dose ratios of 1:2.5, 1:3, or 1:4
Trial: 15078741
Drug: Nimesulide, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide, 100 mg orally twice daily
Trial: 15078741
Drug: Ibuprofen, 400
RxNorm normalized name: Ibuprofen, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen, 400 mg orally three times daily
Trial: 9252814
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (cool packs)
Trial: 27575546
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg RAD1901 daily for 28 days
Trial: 27575546
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg RAD1901 daily for 28 days
Trial: 27575546
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg RAD1901 daily for 28 days
Trial: 27575546
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg RAD1901 daily for 28 days
Trial: 24223362
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus placebo
Trial: 31451367
Drug: Bevacizumab with
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with first-line chemotherapy
Trial: 16931172
Drug: Kcanrenoate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kcanrenoate (100 mg/day)
Trial: 9624787
Drug: Salmeterol xinafoate
RxNorm normalized name: Salmeterol Xinafoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol xinafoate 50 micrograms twice daily via the Diskus inhaler
Trial: 9624787
Drug: Terbutaline sulphate
RxNorm normalized name: Terbutaline sulphate
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline sulphate 500 micrograms four times daily via the Turbuhaler inhaler
Trial: 31599479
Drug: AVB‐S6‐500 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVB‐S6‐500 at a dose of 1 mg/kg
Trial: 31599479
Drug: AVB‐S6‐500 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVB‐S6‐500 at a dose of 5 mg/kg
Trial: 31599479
Drug: AVB‐S6‐500 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVB‐S6‐500 at a dose of 10 mg/kg
Trial: 19214928
Drug: Steroids given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids given acutely for Bell's palsy
Trial: 19214928
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy for Ramsay Hunt syndrome
Trial: 19214928
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy for severe cases of Bell's palsy
Trial: 19214928
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for Lyme facial neuropathy
Trial: 16749407
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg barnidipine
Trial: 9272538
Drug: Cardioversion with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioversion with subsequent antiarrhythmic drug therapy
Trial: 8204701
Drug: Regimen G
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen G (glucose-based TPN)
Trial: 31668693
Drug: Anticholinergic drug
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic drug scale (ADS) score assessment
Trial: 28805611
Drug: Short I-D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short I-D interval (1 mg/kg propofol and 1 μg/kg remifentanil; maintained by continuous infusion of 3 mg/kg/h propofol and 7 μg/kg/h remifentanil)
Trial: 28805611
Drug: Long I-D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long I-D interval (1 mg/kg propofol and 1 μg/kg remifentanil; maintained by continuous infusion of 3 mg/kg/h propofol and 7 μg/kg/h remifentanil)
Trial: 25664962
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Pycnogenol®, roburins, L‐arginine, L‐citrulline
Trial: 22682553
Drug: Abciximab with
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab with unfractionated heparin (UFH)
Trial: 15799844
Drug: OCA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA group (omeprazole 20 mg bid, clarithromycin 500 mg bid, amoxicillin 1000 mg bid)
Trial: 12797399
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) with BCNU
Trial: 12797399
Drug: Bio-chemotherapy (Bio-CT)
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-chemotherapy (Bio-CT) with BCNU
Trial: 12797399
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) without BCNU
Trial: 12797399
Drug: Bio-chemotherapy (Bio-CT)
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-chemotherapy (Bio-CT) without BCNU
Trial: 10760840
Drug: Deramciclane (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deramciclane (0.2 to 50 mg)
Trial: 10760840
Drug: Deramciclane (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deramciclane (50 to 150 mg)
Trial: 619948
Drug: Motival (fluphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motival (fluphenazine 0.5 mg and nortriptyline 10 mg)
Trial: 619948
Drug: Diazepam 7.5
RxNorm normalized name: diazepam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 7.5 mg
Trial: 619948
Drug: Propranolol 60
RxNorm normalized name: propranolol 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 60 mg
Trial: 11929322
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg oral dose of rivastigmine
Trial: 11929322
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravenous dose of rivastigmine
Trial: 24917661
Drug: Single-dose metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose metronidazole (2 grams)
Trial: 15939560
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormonal therapy (conjugated equine estrogens 0.625 mg/die plus medroxyprogesterone acetate 5 mg/die)
Trial: 15939560
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg/die
Trial: 12826986
Drug: Pregabalin 200
RxNorm normalized name: pregabalin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 200 mg tid
Trial: 12826986
Drug: Lorazepam 2
RxNorm normalized name: lorazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2 mg tid
Trial: 12826986
Drug: Pregabalin 50
RxNorm normalized name: pregabalin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 50 mg tid
Trial: 6360431
Drug: Fenfluramine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (60 mg, orally)
Trial: 30577724
Drug: Lecture on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecture on oral health education (OHE) given by dentists
Trial: 30577724
Drug: Lecture on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecture on oral health education (OHE) given by school teachers
Trial: 30323581
Drug: YuPingFeng granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YuPingFeng granules (5 g, three times per day for 1 year)
Trial: 20155991
Drug: Aripiprazole 10
RxNorm normalized name: aripiprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10 mg with simultaneous discontinuation of the current antipsychotic
Trial: 20155991
Drug: Aripiprazole 10
RxNorm normalized name: aripiprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10 mg with tapering off the current antipsychotic over 4 weeks with half the dose after the first 2 weeks
Trial: 20155991
Drug: Aripiprazole 10
RxNorm normalized name: aripiprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10 mg with tapering off the current antipsychotic over 4 weeks after maintenance of the current dose for 2 weeks